INTRODUCTION {#s1}
============

The diagnostic of amplification in the *ERBB2* oncogene leading to the overexpression of the HER2 protein constitutes a paradigm for the use of biomarkers in oncology since trastuzumab, an anti-HER2 antibody, have revolutionized the outcome of *ERBB2*-amplified metastatic breast cancer patients \[[@R1]\]. Routine screening of HER2 overexpression or *ERBB2* amplification is therefore recommended for breast and oesogastric adenocarcinomas on the tumor sample used for the diagnosis \[[@R2], [@R3]\]. HER2 overexpression or *ERBB2* amplification are observed in approximately 20% of metastatic breast cancers \[[@R4]\] and 20% of metastatic oesogastric adenocarcinomas \[[@R5]\]. In breast cancer, it has been shown that *ERBB2* amplification is a marker of poor prognostic that can be reversed by the administration of HER2 inhibitors \[[@R4]\]. This has been one of the best examples of a biomarker that is both prognostic and predictive of treatment response. Trastuzumab has also demonstrated an OS benefit in oesogastric and colorectal adenocarcinomas \[[@R6], [@R7]\].

Besides trastuzumab, several HER2-directed agents have been successfully developed in the clinic; lapatinib, a reversible tyrosine kinase inhibitor (TKI) of EGFR and HER2, trastuzumab emtansine (T-DM1), an antibody-drug conjugate, and pertuzumab in association with trastuzumab have also demonstrated an OS benefit in breast cancer \[[@R8]--[@R10]\].

In addition to amplification, mutations have been described in *ERBB2* that occur at low frequency in several tumor types, especially in breast (3%) \[[@R11]\], colon (2-3%) \[[@R12]\] and lung cancers (1-2%) \[[@R13]\]. The sensitivity of *ERBB2* hotspot mutations p.S310Y, p.L755S and p.V842I to HER2-directed treatments have been recently investigated \[[@R14]--[@R17]\].

Regarding the increasing number of different types of *ERBB2* alterations described across various tumor types, together with the increasing number of HER2-directed therapies, a prospective and systematic evaluation of *ERBB2* alterations and drug sensitivity should help clarifying future personalized treatment decisions. The MOSCATO-01 and 02 programs propose multiple high-throughput genomic analyses on a fresh tumor biopsy to match targeted molecular agents for patients with various types of cancers refractory to conventional treatments \[[@R18]\]. In the MOSCATO-01 study, on the 1036 adult patients included, a molecular analysis has been successfully performed in 844 patients that allowed the administration of a matched targeted therapy in 199 patients. The progression free survival (PFS) with the targeted-therapy (PFS2) was 1.3 times superior to the PFS on the previous treatment line (PFS1) in 33% of patients. Importantly, the highest PFS2/PFS1 ratio in this study has been achieved in the subgroup of patients with *ERBB2* genomic alterations (65%, *n =* 24), leading us to further analyze in depth this molecularly enriched cohort of patients.

The recent approval by the FDA of anti-PD1 immunotherapies for microsatellite instability-High and mismatch repair deficient cancers independently of the tumor types pave the way to broader drug approval for histology-agnostic but biomarker positive patients \[[@R19]\]. A comprehensive evaluation of well-studied biomarkers that lead to treatment approval is required \[[@R20]\]. Programs for the broad evaluation of these strategies, called "umbrella studies", are ongoing for numerous molecular targeted agents \[[@R21]\]. In this regard, we hypothesized that a refined analysis focused on patients with various types of somatic *ERBB2* alterations detected in MOSCATO-01 and ongoing MOSCATO-02 would help to precise the landscape of drug-target relationship.

RESULTS {#s2}
=======

Patient characteristics for pooled MOSCATO-01 and 02 with ERBB2 alterations {#s2_1}
---------------------------------------------------------------------------

From the beginning of MOSCATO-01 in December 2011 until January 2017, 1036 patients were included, and after 8 months of accrual in the MOSCATO-02, 262 more patients were included. On these pooled cohorts of patients 934 had a successful molecular portrait of their tumor (759 CGH and 912 tNGS). A new alteration in the *ERBB2* gene have been found in 4.7% (*n =* 44/934) of patients including 1.5% (*n =* 14/912) *ERBB2* mutations (pathogenic variant), and 4% (*n =* 30/759) *ERBB2* amplifications. These patients were affected 13 different tumor types, and had previously received a median of 3 treatments lines (Table [1](#T1){ref-type="table"}).

###### Patient characteristics

                                                      All patients (*N* = 44)   Evaluable patients (*N* = 31)
  --------------------------------------------------- ------------------------- -------------------------------
  Age at inclusion                                                              
   Median (range)                                     56 (20--77)               57 (30--77)
  Sex                                                                           
   Male                                               24 (55%)                  17 (55%)
   Female                                             20 (45%)                  14 (45%)
  ECOG performance status                                                       
   0                                                  14 (32%)                  12 (39%)
   1                                                  28 (64%)                  18 (58%)
   2                                                  2 (4%)                    1 (3%)
  Tumor type                                                                    
   Head and neck                                      2 (4.5%)                  2 (6.5%)
   Colon                                              3 (7%)                    1 (3.2%)
   Lung                                               6 (13.5%)                 4 (13%)
   Biliary tract cancers                              7 (16%)                   5 (16%)
   Pancreas                                           1 (2%)                    0
   Oesogastric                                        9 (20.5%)                 8 (26%)
   Breast                                             7 (16%)                   5 (16%)
   Cervix                                             2 (4.5%)                  2 (6.5%)
   Endometrial                                        1 (2%)                    1 (3%)
   Urological                                         3 (7%)                    0
   Salivary glands                                    2 (4.5%)                  2 (6.5%)
   Neuroendocrine                                     1 (2%)                    1 (3.2%)
  Number of metastatic sites                                                    
   Median (range)                                     2 (1--4)                  2 (1--4)
  Number of previous therapies for advanced disease                             
   Median (range)                                     3 (0--11)                 3 (0--8)

The frequency of newly detected *ERBB2* amplifications were 25% in oesogastric adenocarcinoma (*n =* 6/32), 13% in salivary gland carcinoma (parotid) (*n =* 2/15), 12% in biliary tract cancers (*n =* 5/42), 5.3% in pancreatic adenocarcinomas (*n =* 1/19), 4.4% in breast cancers (*n =* 6/134), 3% in NSCLC (*n =* 3/101), 3% in colon cancers (*n =* 2/66), 2.3% in urothelial carcinomas (*n =* 1/44) and 1.9% in carcinomas of the head and neck (*n =* 2/105) (Figure [1](#F1){ref-type="fig"}). The frequency of *ERBB2* mutations were 10% in cervix carcinomas (*n =* 2/19), 9% endometrial carcinomas (*n =* 1/11), 3% in NSCLC (*n =* 3/101), 4.5% in urothelial carcinomas (*n =* 2/44), 4.8% in biliary tract carcinomas (*n =* 2/42), 3.1% in oesogastric carcinomas (*n =* 1/32), 1.5% in colorectal carcinomas (*n =* 1/66), 0.7% in breast cancers (*n =* 1/134). No *ERBB2* genomic alterations were found in prostate cancers (*n =* 54), ovarian cancers (*n =* 37) or sarcomas (*n =* 49).

![Distribution of ERBB2 genomic alterations, mutation or amplification, among cancers\
ERBB2 amplifications were mostly found in: salivary gland carcinoma (13%), biliary tract cancers (12%), pancreatic adenocarcinomas (5.3%), lung cancers (3%), with exclusion of breast or oesogastric adenocarcinoma. ERBB2 mutations were mostly found in: cervix carcinomas (10%), endometrial carcinomas (9%), lung cancers (3%), urothelial carcinomas (4.5%), biliary tract carcinomas (*n =* 4.8%).](oncotarget-09-9741-g001){#F1}

The known hotspot mutations in *ERBB2* were also found for several patients in our cohort: p.S310Y (*n =* 6), p.L755S (*n =* 2) and p.V842I (*n =* 2) (Figure [2A](#F2A){ref-type="fig"}). *ERBB2* genomic alterations were frequently associated with *TP53* mutations (58%, *n =* 25/43), and/or other activating or inactivating mutations in the PI3K/AKT/mTOR or the MAPK kinase pathways (26%, *n =* 11/43, Figure [2B](#F2B){ref-type="fig"}). Interestingly, 4.8 % (*n =* 6/128) of patient with a metastatic breast cancer previously diagnosed as HER2-negative were found HER2-amplified in CGH, every case confirmed by immunohistochemistry, which led to the reclassification of these metastatic tumors.

![ERBB2 mutation mapping for drivers mutations (*n =* 14)\
The HER2 protein is represented with known functional sites mapped with different colors reported in the figure legend. The most recurrent hotspot mutations in ERBB2 were p.S310Y (*n =* 6), and the tyrosine kinase domain mutations p.L755S (*n =* 2) and p.V842I (*n =* 2).](oncotarget-09-9741-g002-1){#F2A}

![Co-occurrence between ERBB2 mutation/amplification and other mutations\
Waterfall representation of the altered genes identified in targeted NGS and CGHa, organized relatively to the tumor types. The type of genomic alteration and its functional impact are reported with colors. ERBB2 genomic alterations were frequently associated with TP53 mutations (58%), and/or other activating or inactivating mutations in the PI3K/AKT/mTOR or the MAPK kinase pathways (26%).](oncotarget-09-9741-g002-2){#F2B}

Efficacy of anti-HER2 targeted therapies {#s2_2}
----------------------------------------

On the 31 evaluable patients, 22 were treated with a combination of trastuzumab and chemotherapy (mostly paclitaxel *n =* 13), 6 patients with paclitaxel, trastuzumab and everolimus (due to concomitant mutations in PiK3CA/mTOR pathway), one with neratinib and 2 patients with a combination of trastuzumab and lapatinib. Five patients had breast cancers, 7 oesogastric adenocarcinomas and the remaining 19 patients had 8 different tumor types (Table [1](#T1){ref-type="table"}). Concerning these 19 patients with a tumor type other than breast or oesogastric adenocarcinoma, 8 patients had an *ERBB2* mutation and 11 had *ERBB2* amplification.

For the whole cohort of 31 patients, the CBR was 42% (*n =* 13/31, CI95% \[25--61%\], with 1 CR, 10 PR and 2 SD). For the 19 patients with tumor types other than breast or oesogastric adenocarcinoma, the CBR was 25% (*n =* 2/8 with 2 PR) for *ERBB2* mutation and 64 % (*n =* 7/11 with1 CR, 4 PR, 2 SD \> 24 weeks) for *ERBB2* amplification. The two patients who had a PR in the *ERBB2* mutation subgroup received a combination of paclitaxel, trastuzumab and everolimus for an adenocarcinoma of cervix and an endometrial carcinoma, both harboring *ERBB2* S310Y mutation. For somatic *ERBB2* amplification, all patients that achieved CR or PR were treated with chemotherapy plus trastuzumab (only one received paclitaxel, trastuzumab plus everolimus) (Figure [3](#F3){ref-type="fig"}). For the 19 patients with a tumor type other than breast or oesogastric adenocarcinoma, the median PFS was 4.6 months CI95% \[0.7--8.6\]; for patients with *ERRB2* mutations the median PFS was 2.9 months CI95% \[2.4--3.3\] and for patients with *ERBB2* amplification the median PFS was 6.5 months CI95% \[[@R2]--[@R11]\], without statistical difference in PFS relative to amplifications or mutations (*p =* 0.4, Figure [4](#F4){ref-type="fig"}).

![Best overall response rate during anti-HER2 therapy with exclusion of breast or oesogastric adenocarcinoma\
Best overall response rate was the greater disease in tumor volume under treatment assessed with RECISTS1.1. Patients with early clinical deterioration were arbitrarily put at the maximum observed increase.](oncotarget-09-9741-g003){#F3}

![Progression free survival (PFS) according to ERBB2 mutation or amplification therapy with exclusion of breast or oesogastric adenocarcinoma\
Survival curves were computed with Kaplan Meyer estimation and compared with an unstratified log-rank test.](oncotarget-09-9741-g004){#F4}

DISCUSSION {#s3}
==========

This study has demonstrated that *ERBB2* genomic alterations can be found beyond oesogastric and breast cancers in a wide variety of tumor types at low to moderate frequency (between \<1% and 13%). The molecular profiling of patients with refractory metastatic tumors allowed identifying non previously detected *ERBB2* amplifications in 6 out of 134 patients with breast cancers \[[@R22], [@R23]\]. We have also confirmed the high frequency of *ERBB2* amplifications for 13% of patients with salivary gland carcinoma and 5.2% of patients with biliary tract cancers \[[@R24]\].

ERBB2 genomic alterations are supposed to be driver mutations, but patients from our cohort did not receive anti-HER2 therapies prior to the molecular analysis neither performed prior molecular analysis. Therefore, we could not affirm that these ERBB2 alterations were founder or acquired events.

Targeting HER2 in altered tumors led to a CBR of 42% (*n =* 13/31, CI95% \[25--61%\]), and this benefit was particularly pronounced for *ERBB2* amplifications with a CBR of 64%. These results suggest a strong oncogene addiction to *ERBB2* alterations. In patients with breast and oesogastric adenocarcinoma, results of HER2-directed therapy were consistent with other studies \[[@R1], [@R6]\]. Trastuzumab plus chemotherapy, mainly paclitaxel, was efficient in patients with *ERBB2*-amplified tumors, as previously described in breast, colon, oesogastric adenocarcinoma \[[@R1], [@R6], [@R7]\] and biliary tract cancer \[[@R24]\]. In lung cancer, recent studies showed that a subset of NSCLC is HER2 driven and suggests potential opportunity for HER2 inhibitors in monotherapy or in combination with chemotherapy \[[@R13], [@R14]\]. Moreover in bladder cancer and colon cancer, several studies have showed promising results of HER inhibition in advanced cancer patients \[[@R7], [@R17], [@R25]\].

As patients in the MOSCATO trial were highly pre-treated, the activity of HER2 directed agents may have had a major contribution in the responses even in case of treatment combinations with chemotherapy. We have observed responses for patients with tumor types other than oesogastric or breast and *ERBB2* amplifications. However, we cannot definitely conclude whether the clinical benefit observed in patients was secondary to anti-HER2 directed therapy, chemotherapy or the combination of both. Recently at AACR-NCI-EORTC meeting 2017, E.Ileana *et al.* found *ERBB2* amplifications in 4--14% of various cancer types \[[@R26]\]. In their study they could also confirm that anti-HER2 therapies conferred clinical benefit to patients with tumors beyond classical recommendations.

We found in our study that patients with *ERBB2* mutations had a lower CBR than patients with *ERBB2* amplification, suggesting an influence of the type of alteration on anti-HER2 therapy. However, we should be cautious before drawing a definitive conclusion, since the treatments were not homogeneous and only two patients were treated with a dual anti-HER2 therapy or an irreversible anti-HER2 TKI such as neratinib. The 2 responders treated by chemotherapy plus trastuzumab had an *ERBB2* S310Y mutated tumor, affecting the extracellular domain of HER2, confirming the preclinical demonstration of sensitivity to trastuzumab \[[@R17]\]. Moreover, *in vitro* and *in vivo* data suggest that *ERBB2*-mutated breast cancer are sensitive to neratinib (irreversible anti-HER2 TKI) \[[@R27]\] and that *ERBB2*-mutated colon cancers are more sensitive to dual HER2 inhibition (TKI + Mab) compared to monotherapy or reversible TKI \[[@R16], [@R17]\]. In the clinic, various HER2-directed therapies have demonstrated an overall response rate of 51% (*n =* 101) in *ERBB2* mutated metastatic lung cancer \[[@R14]\]. Another phase II study evaluating dacomitinib, an irreversible tyrosine kinase inhibitor of HER2, EGFR and HER4, has achieved partial responses in 3 of 26 patients with tumors harboring *ERBB2* exon 20 mutations \[[@R28]\]. Concerning *ERBB2*-mutated breast cancers, a phase II has reported a CBR of 31% in 22 patients treated with neratinib \[[@R15]\]. Such approaches have been substantiated in preclinical findings where dual therapy or irreversible anti-HER2 TKI have been shown effective in case of *ERBB2* hotspot mutations \[[@R16], [@R17], [@R27]\]. These observations support the need to tailor the treatment of patients to the type of alterations found in the *ERBB2* gene. Moreover, recent evidences suggest that HER2 inhibitors may be efficient in broader molecular alterations such as *ERBB3* \[[@R25], [@R29], [@R30]\].

Large cohorts of patients, multi histology basket trials or tumor agnostic meta-analysis would be required to clarify the algorithm of treatment decision in case of *ERBB2* and *ERBB3* alterations, based on previous preclinical and clinical data available. Hopefully the increasing size of molecular screening programs for metastatic tumors such as MSKCC IMPACT study \[[@R31]\], the Michigan Center \[[@R32]\] or large screening in lung cancer \[[@R33]\] or MULTIPLI program should help in this direction.

In addition to molecular screening programs, the access to targeted treatment should be reinforced in personalized medicine trials as suggested in SHIVA, SAFIR, MOSCATO and NCI-MATCH trials \[[@R18], [@R34]--[@R36]\]. Furthermore, for relatively frequent alterations across tumors such as *ERBB2*, umbrella or basket designs may be proposed such as in the Acsé programs in France \[[@R37]\]. For example, Hymans and colleagues showed that it is possible to evaluate the efficacy of targeted therapies in an enriched population with a low prevalence molecular alterations such as AKT1 mutations \[[@R38]\], BRAF mutation \[[@R21]\], or NTRK translocation \[[@R39]\].

In conclusion, our data advocate for an enlargement of the screening of *ERBB2* mutations and amplifications beyond breast or oesogastric cancers. Furthers studies are warranted to improve the robustness of the relation between the type of molecular alteration and the clinical effect of the drugs.

PATIENTS AND METHODS {#s4}
====================

Patients included in the study {#s4_1}
------------------------------

The MOSCATO (MOlecular Screening for CAncer Treatment Optimisation, NCT01566019) trial is a molecular screening program to personalize the treatments of patients referred to the early drug development department (DITEP) at Gustave Roussy. The first part of the MOSCATO program has been recently published, and patients accrual is continuing ever since in MOSCATO-02 \[[@R18]\]. An on-purpose tumor biopsy was performed and immediately fresh-frozen for targeted Next Generation Sequencing (tNGS) and comparative genomic hybridization array (CGHa) after histological control. General inclusion criteria of MOSCATO relied on a performance status of 0--1, a refractory or incurable tumor, and a tumor location accessible to biopsy. Importantly, patients with a known molecular alteration that already has a recommended targeted treatment in France were excluded from the study. In the current study, this exclusion criterion concerned patients treated with HER2 inhibitors for an *ERBB2* amplified breast cancer or oesogastric cancer. Compared to the primary analysis of the MOSCATO program, our cohort of patients could be treated by HER2 inhibitors in a variable timeframe after the molecular screening and other patients were included in the ongoing MOSCATO02. This observation has limited our ability to perform comparative analysis with other patients included in MOSCATO-01.

Tumor samples and molecular analysis {#s4_2}
------------------------------------

Methods for tumor sampling and molecular analysis have been described previously \[[@R18]\]. Briefly, tumor biopsies were fresh frozen, tumor cellularity was evaluated histologically, tumor DNA was extracted using DNeasy tissue kit and Qiamp kit respectively (Qiagen, Hilden Germany) according to manufacturer's instructions. tNGS, covering 74 critical oncogenes or tumor suppressor genes (TSG), was performed using Ion torrent (Ion Torrent PGM, Life Technologies^®^). Variant calling was performed with Torrent Suite™ software, variantCaller (v4.x and higher; ThermoFisher Scientific) using GRCh37 (h19) reference. Variants were then annotated using dbsnp (v138) (<http://www.ncbi.nlm.nih.gov/SNP>), COSMIC (v69), and dbNSFP (V2.1), using SnpSift (v4.0E) and somatic variant were filtered from the germline analysis \[[@R40]\] \[[@R41]\]. CGHa was performed using SurePrint G3 Human aCGH Microarray 4 × 180K, Agilent technologies, Palo alto, CA \[[@R42]\]. The copy number alterations detected with CGHa were classified into 5 categories, namely deletion, loss, neutral, gain and amplification, using the GISTIC algorithm \[[@R43]\]. Amplifications in GISTIC confirmed by a \> ×0.7 log2 ratio with a length less than 10 Mb were considered of interest for the current study.

Annotation of ERBB2 mutations {#s4_3}
-----------------------------

To annotated the pathogenicity of the *ERBB2* mutations, we have used SnpEff (v4.0E) and the cbioportal annotation tool \[[@R44]\]. Only pathogenic variants detected in the tumor were selected to orientate the patients to HER2 inhibitors. We have mapped the mutations on a schematic structure of the HER2 membranous receptor using the GenVisR package \[[@R45]\].

Treatments {#s4_4}
----------

Patients harboring a druggable molecular alteration were prospectively oriented and treated in either a phase 1 or an off label use of molecular targeted agent, based on the decision of a molecular tumor board.

Statistics {#s4_5}
----------

Progression free survivals (PFS) were calculated from the first administration of treatment to the date of progressive disease or death. Progressive diseases and response rates were reported according to the RECIST1.1 criteria. Clinical benefit rate (CBR), defined by partial response (PR) or complete response (CR) or stable disease (SD) \> 24 weeks. Survival curves were compared with the use of an unstratified log-rank test. The subgroup of patients with *ERBB2* alteration in tumor other than breast cancer or an oesogastric adenocarcinoma was also analyzed independently.
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